文献速递心力衰竭与心肌病冠心病

肾上腺素与去甲肾上腺素治疗急性心肌梗死后心源性休克的比较

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

这项前瞻性、双盲、多中心随机研究比较肾上腺素与去甲肾上腺素在急性心肌梗死后心源性休克患者中的疗效与安全性。主要疗效终点为心脏指数演变,两组相似(p=0.43);主要安全终点难治性休克在肾上腺素组发生率更高(37% vs 7%,p=0.008),导致研究提前终止。肾上腺素组心率及多项代谢指标变化更不利。

要点

  • 肾上腺素与去甲肾上腺素对心脏指数演变影响相似(p=0.43)。
  • 肾上腺素组难治性休克发生率更高(37% vs 7%,p=0.008)。
  • 肾上腺素组心率增快及代谢不利变化更明显。

核心结论

  • 在急性心肌梗死后心源性休克患者中,肾上腺素与去甲肾上腺素对动脉压和心脏指数影响相似,但肾上腺素组难治性休克发生率更高。

主要发现

  • 主要疗效终点心脏指数演变从基线至72小时两组相似(p=0.43)。
  • 肾上腺素组难治性休克发生率37%(10/27),去甲肾上腺素组7%(2/30),p=0.008,研究因此提前终止。
  • 肾上腺素组心率从2小时至24小时显著增快,去甲肾上腺素组不变(p<0.0001)。
  • 肾上腺素组心脏双重乘积增加(p=0.0002)及乳酸酸中毒(p<0.0001)等代谢变化不利。

关键数值与推荐

  • 难治性休克定义为持续低血压、终末器官低灌注和高乳酸血症,且需要高剂量正性肌力药和血管升压药。

临床怎么用

  • 在急性心肌梗死后心源性休克中,选择升压药时需权衡肾上腺素较高的难治性休克风险及不利代谢影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES: The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS: The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was the occurrence of refractory CS. Refractory CS was defined as CS with sustained hypotension, end-organ hypoperfusion and hyperlactatemia, and high inotrope and vasopressor doses. RESULTS: Fifty-seven patients were randomized into 2 study arms, epinephrine and norepinephrine. For the primary efficacy endpoint, cardiac index evolution was similar between the 2 groups (p = 0.43) from baseline (H0) to H72. For the main safety endpoint, the observed higher incidence of refractory shock in the epinephrine group (10 of 27 [37%] vs. norepinephrine 2 of 30 [7%]; p = 0.008) led to early termination of the study. Heart rate increased significantly with epinephrine from H2 to H24 while remaining unchanged with norepinephrine (p < 0.0001). Several metabolic changes were unfavorable to epinephrine compared with norepinephrine, including an increase in cardiac double product (p = 0.0002) and lactic acidosis from H2 to H24 (p < 0.0001). CONCLUSIONS: In patients with CS secondary to acute myocardial infarction, the use of epinephrine compared with norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of refractory shock. (Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock [OptimaCC]; NCT01367743).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Levy B, Clere-Jehl R, Legras A, et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2018. PMID: 29976291. doi:10.1016/j.jacc.2018.04.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。